一分钟看懂
这是一项关于头颈部肿瘤的II 期研究，登记的药物或干预包括Becotatug Vedotin；Becotatug Vedotin Combined with Penpulimab；Becotatug Vedotin Combined with Ivonescimab，当前状态为招募中。登记地点显示中国成都有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Becotatug Vedotin；Becotatug Vedotin Combined with Penpulimab；Becotatug Vedotin Combined with Ivonescimab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- West china hospital · 成都
公开的入选条件
- 1. Age: 18
- 70 years old, gender not restricted;
- 2. Histopathologically diagnosed as squamous cell carcinoma of the head and neck (including oral cancer, laryngeal cancer, hypopharyngeal cancer, and oropharyngeal cancer, etc.);
- 3. Patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC);
- 4. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;
- 5. Have not received any treatment for head and neck squamous cell carcinoma before, including drug treatment, radiotherapy, surgical treatment, etc.;
- 6. No distant metastasis;
- 7. The patient has the intention for radical treatment;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07381075；登记信息更新于 2026-09-11。